ARTICLE
Googles Wins Right to Sue Google
August 4, 2020
Read time: 1 min

ARTICLE
August 4, 2020
Read time: 1 min

ARTICLE / CLIENT ALERT
August 3, 2020
Read time: 5 min
On July 31, 2020, the US Court of Appeals for the District of Columbia Circuit held that the Centers for Medicare and Medicaid Services (CMS) has authority under the Social Security Act to reduce Medicare payment rates for 340B drugs reimbursed under the Medicare Hospital Outpatient Prospective Payment System (OPPS). This decision reverses a prior district court ruling and preserves the payment cuts for the foreseeable future.
Background
Since 2018, the CMS OPPS rules have reduced hospitals’ Medicare Part B reimbursement for 340B drugs from Average Sales Price (ASP) plus 6% to ASP minus 22.5%, a reduction of almost 30%. Almost immediately after the release of the 2018 Final Rule, a group of hospitals and hospital associations sued the government, alleging that CMS did not have statutory authority to implement the payment cut. In December 2018, the US District Court for the District of Columbia held that, in making these reductions, CMS had exceeded its authority, partly because CMS did not have sufficient data to support the reductions. Our prior On the Subject, “Court Issues Permanent Injunction Blocking Medicare 340B Payment Cuts,” provides an overview of the district court’s decision and analysis.
The DC Circuit Decision
On July 31, 2020, the US Court of Appeals for the DC Circuit reversed the district court’s ruling, finding that CMS’s decision to lower 340B drug reimbursement rates was based on a “reasonable interpretation of the Medicare statute.” The DC Circuit focused on whether CMS “permissibly conceived” of the purposes of the Medicare statute governing OPPS payment rates for 340B drugs when it reduced reimbursement rates for 340B drugs specifically. After analyzing the Medicate statute’s structure, ambiguities and implications, the court found that CMS was permitted to interpret the intent of the statute as compensating hospitals for the costs they incur to acquire outpatient drugs. Based on that interpretation, the court concluded that it was reasonable for CMS to exercise its statutory authority to “adjust” reimbursement rates for 340B drugs to more closely align with hospitals’ costs to acquire those drugs.
Notably, the DC Circuit’s decision was not unanimous. Two of the three judges who heard the case concluded that the reimbursement reduction was permissible, but the third judge found that the reimbursement reduction was unauthorized by statute. She opined that the statute does not authorize CMS to institute large reimbursement reductions for distinct hospital groups (i.e., for 340B covered entity hospitals only) without average acquisition cost data for those hospitals derived from a survey that meets certain requirements. The dissenting judge concluded that, absent that data, CMS must establish reimbursement rates across hospital groups based on ASP, subject to limited adjustments.
The hospital litigants may ask for a rehearing by the full panel of judges at the DC Circuit, and if the litigants do not request such a rehearing, they may further appeal the case to the Supreme Court of the United States. Acceptance of either of these appeal options is discretionary by the applicable court, so there is no guarantee that the litigation will continue or that the hospitals will prevail in any appeal.
Key Considerations
The DC Circuit’s decision is a significant win for the government, as well as for non-340B OPPS hospitals, which benefit from the payment cuts because of budget-neutral redistribution of the reimbursement amounts “saved” through the 340B payment cuts. Further, absent a reversal of the recent DC Circuit decision, it is highly unlikely that 340B OPPS hospitals will receive retrospective OPPS reimbursement for 340B drugs administered or dispensed in 2018, 2019 and 2020, as was contemplated as a potential outcome following the lower court decision.
However, the split decision at the DC Circuit, when viewed in the context of a favorable district court holding, suggests that both CMS and the hospital appellants have arguments that could be persuasive upon further appeal, if such appeal is granted. The hospital associations involved in the litigation have released a joint statement indicating that they “will continue to fight for our hospitals and their patients, and [they] call on CMS to reverse this harmful policy to ensure hospitals can continue to provide the services people need the most.”
Further appeals will require an extended period of time for resolution. For reference, CMS filed its appeal with the DC Circuit in July 2019, more than a year before the court announced its decision. In light of the annual OPPS rulemaking timeframe and the complexity of resolving widespread historic underpayments, hospitals should assume that the 340B payment cuts will continue into the near future.
CMS recently launched a drug acquisition cost survey to collect information regarding 340B hospitals’ net acquisition costs for 340B-purchased drugs, described in our previous On the Subject, “CMS Releases 340B Drug Acquisition Cost Survey, Responses Due May 15, 2020.” CMS indicated that the purpose of the survey was to collect data necessary to establish acquisition cost payment rates for 340B drugs dispensed to hospital Medicare patients. The survey appeared to be an administrative fallback process intended to provide CMS a pathway to continue its reduced reimbursement rates in the event the DC Circuit sided with the hospitals and the district court. However, CMS may also use the survey acquisition cost data to further reduce reimbursement rates for 340B drugs beyond ASP minus 22.5%.

ARTICLE / CLIENT ALERT
August 3, 2020
Read time: 5 min
On July 21, 2020, the US Food and Drug Administration (FDA) issued a long-awaited draft guidance, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry,” which provides insight into FDA’s current thinking on clinical research related to drugs containing cannabis or cannabis-derived compounds. Among the topics addressed are sources for cannabis for clinical research, information and resources for quality considerations, and recommendations for information to include in investigational new drug (IND) applications, including delta-9 tetrahydrocannabinol (THC) calculations.
Crash Course in Cannabis
Cannabis contains more than 80 biologically active chemical compounds, such as the two commonly known compounds delta-9 THC and cannabidiol (CBD). Under the Agriculture Improvement Act of 2018 (2018 Farm Bill), the new definition of “hemp” is “the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a [delta-9 THC] concentration of not more than 0.3 percent on a dry weight basis” (emphasis added). Marijuana, on the other hand, is a term used for varieties of cannabis that contain more than 0.3% delta-9 THC (by dry weight) and can induce psychoactive effects. (The Controlled Substance Act (CSA) uses the spelling “marihuana,” but “marijuana” is the more commonly used spelling and thus is used here throughout.) Therefore, the difference between hemp and marijuana with reference to delta-9 THC is that hemp can contain no more than 0.3% delta-9 THC, whereas marijuana can contain a delta-9 THC percentage of 0.3 or higher. Both hemp and marijuana can be used to produce CBD (hemp-derived CBD versus marijuana-derived CBD).
Although the 2018 Farm Bill did not change the classification of cannabis under the CSA as a Schedule I drug, it did remove “hemp” from the Drug Enforcement Administration’s (DEA’s) regulation under the CSA, such that hemp is no longer considered a controlled substance. Accordingly, CSA-exempt hemp can be distributed and used in interstate commerce as long as the distribution does not violate other federal regulations (such as FDA regulations) or state laws.
State of Cannabis Research Regulation
While providing for DEA exemptions, the 2018 Farm Bill explicitly preserves FDA’s authority to regulate products containing cannabis or cannabis-derived compounds, including human drug products. Under section 201(g) of the Food, Drug, and Cosmetic Act, a drug is a substance “intended for use in diagnosis, cure, mitigation, treatment or prevention of disease in humans or other animals or intended to affect the structure or any function of the body of man or other animals.” A company interested in researching cannabis or cannabis-derived compounds would require an approved IND application to conduct clinical research and obtain the cannabis from a DEA-registered source. For years, the National Institute on Drug Abuse (NIDA) Drug Supply Program, in contract with the University of Mississippi, has been the only DEA-registered source for cannabis. On May 31, 2019, researchers and scientists interested in cannabis research expressed frustration at the lack of available DEA-registered sources for cannabis during FDA’s public hearing, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds.
In its July 20, 2020, draft guidance, FDA clarifies the availability of new options for researchers that do not involve obtaining cannabis from NIDA. Specifically, in light of the 2018 Farm Bill, FDA states that:
Quality Considerations
In the draft guidance, FDA provides suggested resources for quality considerations that a company would need to take into account when preparing an IND for a drug containing cannabis or a cannabis-derived compound. Examples of resources include:
With reference to considerations specific to drugs containing cannabis and cannabis-derived compounds, FDA recommends adequate characterization of cannabis and cannabis-derived compounds to ensure batch-to-batch consistency, quality tests for microorganisms and impurities, and applicable CSA drug scheduling considerations. FDA cautions new drug application applicants to not rely on published literature in place of a full toxicology program to support development of a botanical drug product for phase 3 trials and beyond. FDA further recommends container-closure system and combination product considerations, as needed.
IND Application
FDA recommends that companies provide qualitative laboratory data and detailed testing methods, including testing methods to evaluate the level of delta-9 THC, in particular for phase 2 and 3 studies and marketing applications, which may differ depending on dosage form.
Looking Ahead
On July 22, 2020, FDA also submitted a draft guidance titled “Cannabidiol Enforcement Policy” to the White House Office of Management and Budget for review. FDA has yet to issue any official statements providing additional details regarding the draft guidance, but the cannabis industry has been eagerly anticipating this guidance on FDA’s enforcement position regarding CBD products. We will follow up with a summary of this draft guidance once available for review.
ARTICLE
July 31, 2020
Read time: 1 min

ARTICLE
July 31, 2020
Read time: 3 min
McDermott hosted GE Renewable Energy North America services sales leader Ben Stafford, commercial director of onshore wind for the North Region Rob Bienick, and commercial director of onshore wind for the West Region Matt Lynch on July 30 for a discussion about COVID-19’s impact to turbine supply chain and construction, the effects of the Production Tax Credit (PTC) safe harbor extension and how GE is preparing for 2021 and beyond.
Below are key takeaways from this week’s webinar.
To begin receiving Energy updates, including invitations to the webinar series, please click here.

ARTICLE
July 30, 2020
Read time: 4 min
Without addressing the merits of the claim, the US Court of Appeals for the Seventh Circuit affirmed a district court’s dismissal of a trade secret misappropriation action based on lack of personal jurisdiction, finding no causal relationship between the competitors’ dealings in Illinois and the asserted claims. J.S.T. Corporation v. Foxconn Interconnect Technology Ltd., et al., Case No.19-2465 (7th Cir. July 13, 2020) (Barrett, J.).
In 2005, General Motors (GM) retained Robert Bosch LLC to build a part for some of GM’s cars. To build the part, Bosch required a connector. Bosch turned to JST to design and build the part, which it did for years, becoming the sole supplier of the product to Bosch. After buying 15 million connectors, Bosch allegedly tricked JST into handing over its proprietary technical schematics and designs under the guise that GM required the materials and Bosch would keep them confidential. Instead, Bosch allegedly gave the materials to JST’s competitors, Foxconn and TEC. According to JST, Foxconn and TEC accepted the designs, used them to produce a knockoff connector and displaced JST.
JST filed a lawsuit against TEC and Foxconn affiliates in Illinois for trade secret misappropriation under the Illinois Trade Secrets Act and for unjust enrichment. TEC and Foxconn moved to dismiss the case for lack of personal jurisdiction because none of the defendants were headquartered in Illinois or had a primary place of business there. Further, none of the defendants manufactured or sold the connector in Illinois. JST alleged that TEC and Foxconn sold the connectors to Bosch in Texas and in China, where Bosch installed them into the parts it sold to GM. The only connection to Illinois was the fact that GM sells cars with those parts to dealers in Illinois. Foxconn and TEC argued that this connection was too attenuated to support personal jurisdiction. The district court agreed and dismissed the action. JST appealed.
On appeal, JST asserted that Foxconn and TEC were subject to personal jurisdiction in Illinois because the cars containing the knockoff parts were sold in the state. Relying on the Supreme Court of the United States’ decision in World-Wide Volkswagen, JST argued that personal jurisdiction may be appropriate over “a corporation that delivers its products into the stream of commerce with the expectation that they will be purchased by consumers in the forum State.” The Seventh Circuit observed that its circuit is among those that apply the stream of commerce theory in products liability cases. The Court explained that in the context of a product liability case, the defendant takes steps to reach consumers in a forum state, and the underlying litigation alleges the development of a product that harms consumers.
The Seventh Circuit noted the differences between products liability claims and those involving trade secret misappropriation. The latter is not intrinsically linked to interactions with a consumer and can occur long before an offending product ever reaches a consumer in the forum. Based on the complaint, the Court found that even if Foxconn and TEC acquired the materials from Bosch, designed the connector, manufactured the knockoff and sold their products to Bosch, those actions would have happened in Texas and China—not Illinois.
JST argued that the downstream consumer sales in Illinois damaged its bottom line, which satisfied an element of the tort. Because an element of the tort was satisfied in Illinois, that state necessarily had a close relationship to litigation concerning that tort, JST argued. The Seventh Circuit acknowledged that although this was a clever argument, the focus in World-Wide Volkswagen was the defendant’s conduct, not the plaintiff’s injury. When framing the inquiry correctly on the defendant’s conduct, the Seventh Circuit found the link between the Illinois sales and the alleged misappropriation of JST’s trade secrets too attenuated to support personal jurisdiction, and therefore affirmed the dismissal.

ARTICLE / CLIENT ALERT
July 30, 2020
Read time: 4 min
In an announcement welcomed by many healthcare providers, on July 23, 2020, the US Department of Health and Human Services announced that the COVID-19 public health emergency would be extended 90 days, through October 23, 2020. While this enables providers to continue operating under the waivers and other relief extended as a result of the pandemic, they should use this window of opportunity to prepare for a return to pre-public health emergency operations.
Providers around the country that have relied upon the waivers and flexibilities afforded under Section 1135 of the Social Security Act (Act) and other rulemaking welcomed the July 23, 2020, announcement by the US Department of Health and Human Services (HHS) that the public health emergency (PHE) in relation to the COVID-19 pandemic would be extended for 90 days, through October 23, 2020 (unless earlier terminated by the Secretary of HHS). This PHE extension functioned to keep in place the waivers under Section 1135 of the Act, including those involving the use of alternate care sites, reduced regulatory reporting burdens, and compliance with certain facility conditions or requirements for participation.
As noted in our prior client alert, both the HHS declaration and the presidential declaration must be in effect to maintain much of the waiver relief that many types of healthcare providers and facilities have utilized in responding to the unique and unprecedented needs brought about by the pandemic. While the presidential declaration remained in force, the HHS declaration was due to expire on July 25, 2020. Prior to the extension, providers expressed concern that the PHE declaration may not be renewed, which would have triggered a cascade of effects as the waiver relief simultaneously expired.
In light of increasing case counts and hospitalization surges in numerous states, it remains uncertain how long providers will need the benefit of waivers to provide services; however, it makes it less likely that the Secretary will end the PHE before the October 23, 2020, date. Regardless, the extension of the PHE provides an opportunity for providers to lay the groundwork for a return to pre-PHE operations, smoothing the transition that will come with the end of the PHE in the future.
Key Takeaways
The extension of the PHE into October was welcome news for providers that have become accustomed to operating under the Section 1135 waivers and other regulatory flexibilities. Without new legislation and modification of existing regulations, many of the waivers and flexibilities will expire along with the PHE in October, and no regulatory pathway currently exists for a “phased” or stepwise approach to pre-PHE operations.
Accordingly, during this extension period, it would be prudent for providers to:

ARTICLE / CLIENT ALERT
July 30, 2020
Read time: 3 min
In March, we wrote about the challenges self-isolation and social-distancing presented to the legalities of signing a will, in particular the requirement that a will is signed in the presence of at least two witnesses. We suggested a technological solution available in the form of electronic signatures for the testator and the two witnesses being present via a video meeting.
The Ministry of Justice has now announced that the Government is introducing legislation to temporarily allow people to use video-conferencing technology for the witnessing of wills by extending the definition of ‘presence’ of those making and witnessing wills to include a virtual presence. The amendment in and of itself sounds promising, however, as a wet signature is still required and the witnesses will still have to sign the same document, the practical challenges and health risks remain. If someone at risk is shielding and cannot attend an in-person signing, does it really help them if they instead need to go to the Post Office?
The Government guidance outlines a 5 stage signing and witnessing process that makes it possible for a person to sign a will in the presence of two witnesses by way of a two or three way video-link. Following the initial video-conference, the will document must be taken to the two witnesses (ideally within 24 hours) who must then sign the same will document by way of a further video conference. Not only does the act of sending the will document seem contradictory to the goal of protecting people shielding or self-isolating but there are additional risks associated with the built-in delay of the will physically moving between the testator and witnesses – that the testator may die during the period of delay, of the will becoming lost, getting damaged and potentially the risk of fomite transmission of COVID-19 as the document passes between households.
The decision not to allow electronic signatures, even on a temporary basis, offers no real solution for those shielding and self-isolating. The Law Commission has been reviewing the legislation in relation to wills since July 2017 and while we are told that they will be considering the possibility of electronic wills sometime in the future, the legislation remains largely as it did in 1837. The legislation needs to be modernised to take into account societal and technological changes, now more than ever.

ARTICLE / CLIENT ALERT
July 29, 2020
Read time: 5 min
On July 20, 2020, the Office for Civil Rights (OCR) at the US Department of Health and Human Services (HHS) issued guidance focused on federal financial assistance recipients’ compliance with Title VI of the Civil Rights Act of 1964. Title VI prohibits discrimination on the basis of race, color or national origin. The bulletin also highlights initiatives and funding opportunities by OCR and HHS focused on removing discriminatory barriers that impede equal access to quality healthcare.
As the novel Coronavirus (COVID-19) pandemic continues to affect the United States, current data from the Centers for Disease Control and Prevention (CDC) suggests that the virus disproportionately affects racial and ethnic minority groups. To help ensure that these disparities are addressed, the Office for Civil Rights (OCR) at the US Department of Health and Human Services (HHS) issued a bulletin guidance document on July 20, 2020, titled “Civil Rights Protections Prohibiting Race, Color and National Origin Discrimination During COVID-19.”
The bulletin focuses on federal financial assistance recipients’ compliance with Title VI of the Civil Rights Act of 1964. Title VI prohibits discrimination on the basis of race, color or national origin by recipients of federal financial assistance. Title VI prohibits “both intentional discrimination and methods of administration that have a disproportionate and adverse impact on the basis of race, color, or national origin.”
The bulletin provides specific guidance points to help ensure Title VI compliance by funding recipients, including:
In addition to providing guidance on how to comply with Title VI, the bulletin highlights several OCR and HHS initiatives to “identify the populations most vulnerable to COVID-19 and to improve prevention, testing, and treatment in these populations.” These initiatives include:
Key Takeaways
As federal funding recipients, including state and local agencies, hospitals and other healthcare providers, continue to take steps to serve their communities and address the COVID-19 public health emergency, the OCR bulletin reminds these recipients of federal funds to ensure that they are adequately and appropriately serving their entire community. Undertaking additional compliance efforts in a time of limited resources and amid the unique demands of the pandemic may be challenging for providers, but OCR continues to place a priority on taking active steps to address health inequities affecting minority communities and to remove discriminatory barriers that impede equal access to quality healthcare.

ARTICLE
July 29, 2020
Read time: 1 min